Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 213559, held by Quagen. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 213559 (Triamcinolone Acetonide), held by Quagen, was first approved by FDA on Jul 1, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2020 | Original application | Approved | None posted |
| Triamcinolone Acetonide0.025% · lotion;topical | Triamcinolone Acetonide | Rx |
| Triamcinolone Acetonide0.1% · lotion;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
